R1 RCM Inc. (NASDAQ:RCM) Receives $16.87 Average PT from Analysts

Shares of R1 RCM Inc. (NASDAQ:RCM) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.87.

Several analysts have recently weighed in on RCM shares. Morgan Stanley restated an “overweight” rating and set a $17.00 target price on shares of R1 RCM in a research note on Tuesday, March 26th. SVB Leerink started coverage on shares of R1 RCM in a research note on Monday, February 26th. They issued an “outperform” rating and a $14.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $19.00 price objective on shares of R1 RCM in a report on Thursday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of R1 RCM in a report on Wednesday, April 10th. Finally, Truist Financial reissued a “hold” rating and set a $16.00 price target on shares of R1 RCM in a research report on Monday, April 1st.

Insider Buying and Selling at R1 RCM

In related news, President John M. Sparby sold 10,046 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $14.33, for a total value of $143,959.18. Following the completion of the transaction, the president now directly owns 265,986 shares of the company’s stock, valued at approximately $3,811,579.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 36.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On R1 RCM

A number of institutional investors have recently added to or reduced their stakes in RCM. Headlands Technologies LLC purchased a new stake in R1 RCM during the third quarter valued at about $36,000. ANTIPODES PARTNERS Ltd lifted its holdings in shares of R1 RCM by 429.5% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock valued at $59,000 after purchasing an additional 4,561 shares in the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of R1 RCM in the fourth quarter worth $61,000. Van ECK Associates Corp grew its holdings in shares of R1 RCM by 20.5% during the fourth quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock valued at $65,000 after buying an additional 1,044 shares in the last quarter. Finally, Caas Capital Management LP acquired a new position in R1 RCM during the fourth quarter valued at $148,000. 61.10% of the stock is currently owned by institutional investors and hedge funds.

R1 RCM Price Performance

NASDAQ RCM opened at $12.45 on Friday. The company’s fifty day simple moving average is $12.91 and its 200-day simple moving average is $11.45. R1 RCM has a 52 week low of $8.87 and a 52 week high of $18.70. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.83 and a quick ratio of 1.83.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.